Please use this identifier to cite or link to this item:
Title: What is the optimal drug-eluting stent for percutaneous coronary intervention in patients with insulin-treated vs. non-insulin treated diabetes?
Author: Blusztein, D.
Biswas, S.
Lefkovits, J.
Ajani, A.
Brennan, A.
Stub, D.
Duffy, S.
Chan, W.
Clark, D.
Freeman, M.
Oqueli, Ernesto
Reid, C.
Yudi, M.
Hutchison, A.
Dawson, L.
Murphy, A.
Eccleston, D.
Issue Date: 2019
Conference Name: 67th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 13th Annual Australia and New Zealand Endovascular Therapies Meeting.
Conference Date: August 8th-11th
Conference Place: Adelaide, Australia
Abstract: Background: Patients with diabetes mellitus (DM) have increased adverse events post percutaneous coronary intervention (PCI), somewhat attenuated by use of drug-eluting stents (DES). DES choice is controversial, with studies showing increased late mortality with sirolimus-eluting stents (SES) compared to paclitaxel-eluting (PES) or bare-metal stents (BMS) and higher major adverse cardiac and cerebrovascular event (MACCE) rates with second generation everolimus (EES) vs. PES. Methods: We enrolled 4,579 diabetic patients undergoing PCI from 2005-2014 in the Melbourne Interventional Group registry. Characteristics and 12-month outcomes were compared between insulin-treated (ITDM) and non-ITDM patients and by stent type. Results: Diabetics receiving DES were more likely to be insulin-requiring ( p < 0.05) or undergoing PCI for restenosis ( p < 0.001). ST-elevation myocardial infarction (STEMI) patients more often received BMS ( p < 0.003 for SES and PES); even after propensity matching in STEMI, a significant hazard for MACCE in ITDM vs. non-ITDM patients (OR 1.48, 1.19-1.84) remained. Stents were longer and vessel size smaller in DES vs. BMS ( p < 0.0001). However, 12-month MACCE were higher in BMS vs. SES or PES ( p = 0.004 and p = 0.046) and did not differ between DES types. Conclusion: In ITDM, all DES resulted in lower 12 month MACCE than BMS. Overall, outcomes depend more on the presence and intensity of DM treatment than stent type, particularly for EES vs. PES or second-generation vs. first generation DES.
Resource Link:
Internal ID Number: 01377
Type: Conference
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.